Protara Therapeutics Inc (TARA)

NASDAQ
6.37
+0.05(+0.79%)
After Hours
6.75
+0.38(+5.97%)
- Real-time Data
  • Volume:
    28,158
  • Bid/Ask:
    5.91/6.75
  • Day's Range:
    6.10 - 6.39

TARA Overview

Prev. Close
6.32
Day's Range
6.1-6.39
Revenue
-
Open
6.26
52 wk Range
5.94-22.98
EPS
-4.08
Volume
28,158
Market Cap
71.57M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
101,994
P/E Ratio
-
Beta
0.81
1-Year Change
-67.18%
Shares Outstanding
11,235,731
Next Earnings Date
10 Mar 2022
What is your sentiment on Protara Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Protara Therapeutics Inc Company Profile

Employees
27

Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is intravenous (IV) substrate replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD). Vonapanitase is a recombinant human elastase that are developing for the improvement of vascular access outcomes in patients with chronic kidney disease.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuySellStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.